The chemical conglomerate is the second firm to license CRISPR/Cas9 from the Broad after Monsanto.
The program will provide two young scientists with funding for independent research as well as resources to help them commercialize their technology.
The gene-gene interactions research could lead to new therapies targeting cells with particular mutations, or combinations of targeted therapies.
The Croatan algorithm uses the random forest machine learning method to evaluate guide RNAs for use in CRISPR knockout experiments.
The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.